title: P504S expressing circulating prostate cells as a marker for prostate cancer.
abstract: Prostate cancer is the most commonly diagnosed cancer in men and the second leading cause of cancer deaths. The serum prostate specific antigen (PSA) is the only biomarker routinely used in screening. The aim of this study was to develop a system to test the presence of circulating prostate cells in men without a diagnosis of prostate cancer in relation with age, serum PSA levels and prostate biopsy by determining the co-expression of several markers such as CD82, HER-2 and matrix metalloproteinase 2 (MMP-2). For this purpose mononuclear cells were separated from blood using differential centrifugation and then prostate cells were identified by using standard immunocytochemical method. Results indicated that among 409 men screened for prostate cancer 16.6% were positive for circulating prostate cells. Cells were positive for MMP-2 and HER-2 in 100 and 14.3% of cases, respectively, without an association with age or PSA levels. However, CD82 protein expression was associated with older age and low grade tumors. It can be concluded that the study of circulating prostate cells with various markers could be a useful complementary screening test for prostate cancer in men with increased PSA level.
authors.affiliation: Subdivisión de Hematologóa, Hospital de Carabineros, Nuñoa, Santiago, Chile. nigelpetermurray@gmail.com
authors.forename: Nigel P
authors.initials: NP
authors.lastname: Murray
authors.forename: Gloria M
authors.initials: GM
authors.lastname: Calaf
authors.forename: Leonardo
authors.initials: L
authors.lastname: Badinez
authors.forename: Ricardo
authors.initials: R
authors.lastname: Dueñas
authors.forename: Orlando
authors.initials: O
authors.lastname: Badinez
authors.forename: Nelson
authors.initials: N
authors.lastname: Orellana
authors.forename: Eduardo
authors.initials: E
authors.lastname: Reyes
authors.forename: Cinthia
authors.initials: C
authors.lastname: Fuentealba
mesh_terms: D000367:Age Factors; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001706:Biopsy; D002469:Cell Separation; D016009:Chi-Square Distribution; D002677:Chile; D006801:Humans; D007150:Immunohistochemistry; D051861:Kangai-1 Protein / Q000097:blood; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000378:metabolism* / Q000473:pathology; D011237:Predictive Value of Tests; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology; D019998:Racemases and Epimerases / Q000097:blood*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood
chemical_list: D014408:Biomarkers, Tumor; D051861:Kangai-1 Protein; D020778:Matrix Metalloproteinase 2; D017430:Prostate-Specific Antigen; D019998:Racemases and Epimerases; D018719:Erb-b2 Receptor Tyrosine Kinases; C497688:CD82 protein, human; C508053:ERBB2 protein, human; C522361:MMP2 protein, human; C108352:alpha-methylacyl-CoA racemase